The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Biopharmaceutical benchmarks 2018
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“between 2014 and 2018 the vast majority (84%) of newly approved antibody therapeutics were produced in CHO cells [5].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [5]
In the citing paper
“Coming back to Ig-based biotherapeutics, atezolizumab, an oncolytic anti-PD-L1 mAb, is another clinically approved (2016-US, 2017-EU) glycoengineered product, except the Fc has been engineered to lack glycosylation [5].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [5]
In the citing paper
“CHO cells have become dominant in biotherapeutic production because they produce non-immunogenic and near human-like glycosylation [5].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [5]
Citations
Cites
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76
Flagged first, then by citations
Research works printed but not linked: 11
- Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992–1000 (2014). · DOI · Paper page
- Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010). · DOI
- Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006). · DOI
- Bertolini, L.R. et al. The transgenic animal platform for biopharmaceutical production. Transgenic Res. 25, 329–343 (2016). · DOI
- Park, T.S. et al. Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter. FASEB J. 29, 2386–2396 (2015). · DOI
- Miliotou, A.N. & Papadopoulou, L.C. CAR T-cell therapy: a new era in cancer immunotherapy. Curr. Pharm. Biotechnol. 19, 5–18 (2018). · DOI
- Kaplon, H. & Reichert, J.M. Antibodies to watch in 2018. MAbs 10, 183–203 (2018). · DOI
- Zheng, P.P., Kros, J.M. & Li, J. Approved CAR-T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 23 1175–1182 (2018). · DOI
- Labanieh, L., Majzner, R.G. & Mackall, C.L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391 (2018). · DOI
- Köhl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559–568 (2018). · DOI
- Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. Immunol. Rev. 270, 193–208 (2016). · DOI
Cited by
Sorted by citations
Items 801–849 of 849
Nakamura, A., Kadowaki, M., Tsujioka, K., Kaieda, T., & Kamihira, M. (2025) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2025.08.004
Ransdell, A. S., Reed, M., Herrington, J. D., Hougland, M., & Kelly, R. M. (2025) · Journal of Chromatography Open · doi:10.1016/j.jcoa.2025.100263
Wang, Y., Chen, X., Schwarz, H., Chotteau, V., & Jacobsen, E. W. (2026) · Journal of Process Control · doi:10.1016/j.jprocont.2026.103632
“To demonstrate the e ff ectiveness of the proposed method, we revisit the introductory example in Section 2.”
Buslaeva, E. A., Аlikina, S. А., Хасаншина, З. Р., Kriazhevskikh, L. М., Kucherenko, А. N., & Васильевич, Д. Р. (2025) · Drug development & registration · doi:10.33380/2305-2066-2025-14-3-2064
Gao, L., Li, X., Zhang, M., Li, B., Miao, X., Yu, C., Guo, W., Zhang, C., He, X., Huang, K., et al. (2025) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-025-03200-x
“Chinese hamster ovary (CHO) cells are widely recognized as the preferred host for the large-scale commercial production of therapeutic proteins [1], owing to their high productivity, human-like post-translational modifications, and stable transgene expression [2].”
Vaccaro, M., Polito, G., Bagaglini, G., Capuozzo, M., Langella, R., Nava, E., Zovi, A., & Ferrara, F. (2025) · Journal of Healthcare Quality Research · doi:10.1016/j.jhqr.2025.101148
Glycosylation-enabled Site-specific Growth Factor Engineering for Biomaterial FunctionalizationPreprint
Xing, Y., Li, Q., Campbell, P. G., & Ren, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.652418
“Our strategy leverages the intrinsic ability of mammalian cells to perform post-translational glycosylation, a natural biosynthetic process that ensures recombinant proteins like VEGF165 are naturally modified with glycan chains during production [46-48].”
Functional Analysis of Mature Activin A Produced by Enterokinase in Plant Cells
Moon, K.-B., Park, J.-S., Kim, H.-G., Jeon, J., Kwon, T., Chung, K.-S., Lee, H.-J., & Kim, H.-S. (2025) · Rice · doi:10.1186/s12284-025-00775-7
“However, they require high costs and complex culture facilities (Kim et al. 2014; Walsh 2018).”
Загорская, А. А., & Дейнеко, Е. В. (2024) · Fiziologiâ rastenij · doi:10.31857/s0015330324050037
Advancements in Pharmaceutical Technology: Shaping the Future of Medicine
Malau, J. (2024) · Journal of Health and Nursing. · doi:10.58738/jhn.v2i1.650
“These products are designed using living cells and genetic engineering techniques, offering highly targeted therapies for diseases like cancer and autoimmune disorders (Walsh, 2018).”
Isolation and characterization of rabies monoclonal antibody charge variants
Divase, A., Pisal, S. S., Dake, M. S., Dakshinamurthy, P. K., Reddy, P. A., Dhere, R. M., Kamat, C. D., Chahar, D. S., Pal, J. K., & Nawani, N. N. (2024) · Electrophoresis · doi:10.1002/elps.202300221
Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors.
Dannemeyer, M., Berling, A., Kanje, S., Enstedt, H., Xu, L., Afshari, D., Westin, M., Jensen, G., Uhlen, M., Hober, S., et al. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106505
Gao, J., Hazeltine, L. B., Stroud, N., Liu, N., & Huang, Y. (2024) · Biotechnology Progress · doi:10.1002/btpr.3423
Yamaguchi, T., Fukuda, M., Matsumoto, Y., Mori, T., Kikuchi, S., Nagano, R., Yamamoto, K., & Wakamatsu, K. (2023) · Cytotechnology (Dordrecht) · doi:10.1007/s10616-023-00587-x
Plasmazellen als Blaupause für die moderne Biopharmakaherstellung
Zeh, N., Raab, N., & Otte, K. (2022) · BIOspektrum · doi:10.1007/s12268-022-1827-1
“[1] Walsh G (2018) Biopharmaceutical benchmarks 2018.”
BackgroundGarcía-Pardo, J., Montané, S., Avilés, F., Tanco, S., & Lorenzo, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102138
“Examples of recently approved pharmaceutical products obtained with this system include monoclonal antibodies, hormones, clotting factors, and enzymes [1,7].”
BackgroundÇekiç, E. G., Alkan, A., Tarhan, E., & Tanriverdi, O. (2022) · Muğla Sıtkı Koçman Üniversitesi tıp dergisi · doi:10.47572/muskutd.1096902
Omasa, T. (2022) · Yakugaku Zasshi-journal of The Pharmaceutical Society of Japan · doi:10.1248/yakushi.21-00211-1
High‐Performance Liquid Chromatography–Mass Spectrometry in Peptide and Protein Analysis
Shen, T. (2021) · Wiley eBooks · doi:10.1002/9780470027318.a1618.pub4
Factors Affecting the Implementation of Specialized Skills of Therapist in Special Education Centers
Mumtaz, A., Saeed, B., Khan, M. S. G., Noreen, H., RashidH, M., Masood, F., RuhamahY, M., & Askri, S. M. H. (2021) · Pakistan Journal of Medical & Health Sciences · doi:10.53350/pjmhs211582107
“According to Walsh (2018) this is now it is not uncommon for these misconceptions that precise education is the least relevant part of the general faculty device; this assumption is incorrect, as in many, special education requires more challenging and more difficult than general education.”
BackgroundHussain, H., McKenzie, E. A., Robinson, A. M., Gingles, N., Marston, F., Warwicker, J., & Dickson, A. J. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11405-9
“Escherichia coli (E. coli) remain the preferred used bacterial expression system, due to the low cost, rapid growth and high-cell densities achieved (Walsh 2018).”
Arnesen, J. A., Nielsen, J. B., Kildegaard, H. F., & Borodina, I. (2021) · Metabolic Engineering · doi:10.1002/9783527823468.ch10
Growth and eGFP-production of CHO-K1 suspension cells cultivated from single-cell to lab-scale
Schmitz, J., Hertel, O., Yermakov, B., Noll, T., & Grünberger, A. (2021) · bioRxiv · doi:10.1101/2021.05.20.444654
“The number of biotechnologically manufactured products like biopharmaceuticals increased rapidly 33 over the last decades (Walsh 2018).”
BackgroundMulyanti, D., Soewandhi, S. N., & Riani, C. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06562-z
Біотехнологічні лікарські препарати: науково-регуляторні та навчально-методичні аспекти
Зайченко, Г. В., Горчакова, Н., Шумейко, О., Клименко, О., Ходаківська, О., & Мироненко, В. (2020) · Біомедична інженерія і технологія · doi:10.20535/2617-8974.2020.4.221815
“leukocytes during chemotherapy and reduce the risk of secondary infection of the patient [13].”
BackgroundMorowvat, M. H. (2020) · Koomesh journal · doi:10.29252/koomesh.22.3.505
Ding, Y.-F., Zhang, J.-W., Xia, M.-J., Wu, G., Li, W., Feng, D., & Gong, S.-W. (2020) · doi:10.21203/rs.3.rs-23749/v2
“Although in the past 15 10 years, more than half of the top ten drugs sold worldwide were mAbs, the clinical 16 application of mAbs in China is still limited [8,25].”
BackgroundTriggering outer membrane leakiness of a novel E. coli strain for recombinant protein production
Kastenhofer, J., Rettenbacher, L. A., Feuchtenhofer, L., Mairhofer, J., & Spadiut, O. (2020) · doi:10.21203/rs.3.rs-21294/v1
“In the biopharmaceutical sector in 2018, it produced 22% of all therapeutic proteins with active licenses in the USA and the EU [4].”
BackgroundRawat, J., & Gadgil, M. (2019) · Biochemical Engineering Journal · doi:10.1016/j.bej.2019.107436
Addressing Bioanalytical Needs of Antibody-Based Biotherapeutics by LC-MS
Faria, M. (2020) · doi:10.17145/jab.20.003
“Antibody-based biotherapeutics are the fastest growing category of therapeutics entering clinical studies [1].”
BackgroundPreparing Proteoforms of Therapeutic Proteins for Top-Down Mass Spectrometry
Hidayah, S. N., Gaikwad, M., Heikaus, L., & Schlüter, H. (2019) · Proteoforms - Concept and Applications in Medical Sciences · doi:10.5772/intechopen.89644
Müller, P. (2019) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-19531
“Recently, two pegfilgrastim biosimilars have been approved for the US market (Fulphila®)(Walsh 2018) and European market (Ziextenzo®)(Press release Sandoz 27.11.2018).”
BackgroundResultInfluentialLucas, P. (2019) · doi:10.70675/271dc704zf26fz4fa2zbe4dzeb79449a2fac
“A titre d’exemple, sur la période allant de 2014 à 2018, plus de 80% des protéines recombinantes thérapeutiques acceptées sur le marché ont été produites au sein du système CHO (Walsh, 2018).”
BackgroundBlundell, P., Lu, D., Dell, A., Haslam, S., & Pleass, R. (2019) · bioRxiv · doi:10.1101/719849
“The aim of the current study was to reveal possible 465 variation in functional glycosylation related to differences in two host cell lines, 466 CHO-K1 and HEK 293-F, particularly as antibodies and Fc fusions are the 467 fastest growing therapeutic class in the pharmaceutical industry (26, 37, 38).”
BackgroundZaychenko, A., Gorchakova, N., Shumeiko, E., Klymenko, E., & Chodakovskaya, O. V. (2019) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs04.04.224
Protein structure, activity and thermal stability within nanoscopic compartmentsPreprint
Cecchin, D., Tian, X., Kluthe, K. E. I., Poma, A., Ruiz‐Pérez, L., LoPresti, C., & Battaglia, G. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1607.08886 · Cited by 2
“ramifications across several areas ranging from protein therapeutics to the food industry (9)(10).”
BackgroundNavigating the complexity of biologics and biosimilar: structural, clinical, and regulatory insights
Nagarajan, B., Anandbabu, T., Lakshmi, K., Neethirajan, G., Dabburu, K., Prasanna, P., Grace, D. C., Prabha, K., & Vasudevan, E. (2026) · Journal of Applied Biology & Biotechnology · doi:10.7324/jabb.2026.274436
“A landmark achievement in recombinant protein therapeutics was the approval of recombinant human insulin in 1982, which not only revolutionized diabetes care but also validated recombinant DNA technology as a viable pharmaceutical platform [16].”
Biopharmaceutical Production in Plant-Based Systems: Current Status and Future Prospects
Kumar, S. A., & Priyanka, D. (2024) · International Journal of Biological and Environmental Investigations · doi:10.33745/ijzi.2024.v10i01.019
“However, these methods were laborious and limited in scalability (Walsh, 2018).”
MethodEukaryotic Aggresomes: Protocols and Tips for Their Production, Purification, and Handling
Mendoza, R., Ferrer‐Miralles, N., & Corchero, J. L. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1859-2_25 · Cited by 1
A model-based framework for integrated process design and flexibility analysis
Sachio, S., Kontoravdi, C., & Papathanasiou, M. M. (2022) · arXiv.org · doi:10.48550/arxiv.2212.10946
“The rising demand for biopharmaceuticals is dictating the advancement of current processes towards more efficient operation [1-3].”
BackgroundGuttman, A., & Hajba, L. (2022) · Capillary Gel Electrophoresis · doi:10.1016/b978-0-444-52234-4.00001-5
Biopharmaceutical Applications
Wan, Q. (2021) · Mixed-Mode Chromatography · doi:10.1007/978-981-16-5485-5_10
Monoclonal Antibody Glycoengineering for Biopharmaceutical Quality Assurance
Gómez, I. A., & del Val, I. J. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_6
Heterologous Protein Expression in Yeast and Molds
Mohanty, S., Babbal, & Khasa, Y. P. (2021) · Springer eBooks · doi:10.1007/978-981-16-3307-2_21 · Cited by 1
Plant biotechnology;an important avenue for medicine during pandemics
Khan, T., Amin, I., Adil, M., Alam, S., Khan, S., Amin, U., Ullah, I., Aasim, M., & Khan, M. (2021) · doi:10.53560/ppasb(58-sp1)656
“In 2017, The estimated market worth of monoclonal antibodies was 123 billion USD, of which 87% mAb products were produced in CHO cells [9].”
BackgroundLarge Biomolecules: An Overview
Behera, B., Prasad, R., & Behera, S. (2020) · doi:10.1007/978-981-15-7590-7_1
Schmelzer, B., Altvater, M., Gasser, B., Sauer, M., & Mattanovich, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-49924-2_13 · Cited by 2
Eukaryotic Expression Systems for Upstream Processing of Monoclonal Antibodies
Heistinger, L., Reinhart, D., Mattanovich, D., & Kunert, R. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-54630-4_13 · Cited by 2
Exploring the Complex Folding Free Energy Landscapes of a Series of β-rich Proteins
Cohen, N. R. (2019) · eScholarship@UMassChan · doi:10.13028/jvnr-fd46
Metadata
- Authors
- Walsh, G.
- Affiliations
- University of Limerick (IE)
- Corresponding author
- Walsh, Gary
- ORCID
- Walsh, Gary
- Venue
- Nature Biotechnology
- Published
- 2018-12
- Volume
- 36
- Issue
- 12
- Pages
- 1136-1145
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2917928050
- Cited by
- 978
- References
- 15
- Citations by year
- 2026: 68 · 2025: 68 · 2024: 88 · 2023: 141 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 65
- FWCI
- 165.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- biopharmaceutical market, monoclonal antibodies, cell therapy, gene therapy, biosimilars, biologics, market growth
- MeSH terms
- Animals, Antibodies, Monoclonal, Biological Products, Biotechnology, Drug Industry, European Union, Humans, Nucleic Acids, Recombinant Proteins, United States, United States Food and Drug Administration, Drug Approval, Benchmarking, Biosimilar Pharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
